<DOC>
	<DOCNO>NCT01518517</DOCNO>
	<brief_summary>Asparaginase cornerstone treatment ALL , utility limited toxicity include hypersensitivity . Clinical allergy associate inactivation asparaginase antibody ( A-Abs ) , also neutralize asparaginase without clinical sign hypersensitivity ( silent inactivation ) . GRASPA improve pharmacokinetics , tolerability maintain circulate asparaginase activity due protective barrier erythrocyte membrane . This study run confirm benefit/risk profile GRASPA 150 IU/kg combination COOPRALL regimen adult child patient relapse ALL , without know hypersensitivity L-asparaginase .</brief_summary>
	<brief_title>GRASPA ( Erythrocytes Encapsulating L-asparaginase ) Patients With Relapse Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>This open , randomized international Phase 2/3 study enrol patient relapse ALL . The co-primary endpoint duration asparagine depletion &lt; 2µmol/L incidence asparaginase hypersensitivity induction . Key secondary endpoint complete remission ( CR ) , minimal residual disease ( MRD ) , event free survival ( EFS ) overall survival ( OS ) .The study power detect 3-fold difference incidence allergic reaction treatment . patient randomize GRASPA Reference L-asparaginase . Patients history hypersensitivity previous L-asparaginase treatment treat GRASPA ( exploratory arm )</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<criteria>Patient 1 55 year old ( Children adolescents 1 17 years/ Adults 18 55 year ) Patients 1st ALL relapse , could either isolate bone marrow relapse , combine ( medullary extramedullary ) relapse , extramedullary isolate relapse ; lymphoblastic lymphoma ( except Burkitt lymphoma ) OR Failure ALL first line treatment ( complete remission obtain ) Patient previously treat free E.Coli Lasparaginase form pegylated one Performance Status ≤ 2 ( WHO score ) Patient inform consent provide ( 2 parent need consent child 18 ) ALL ( 9 ; 22 ) and/or BCRABL positive ( Philadelphia chromosome positive ) Patient 2nd relapse Women childbearing potential without effective contraception well pregnant breast feed woman Patient unable receive treatment use global chemotherapy protocol , due general visceral condition : Severe cardiac impairment ( NYHA grade 3 4 cardiomyopathy ) /Serum creatinine 2 x ULN unless relate ALL /ALT AST 5 x ULN unless relate ALL /Pancreatitis history /Other malignancy ALL / Severe Infection , HIV positive , active hepatitis relate B C virus infection / Trisomy 21 / Other serious condition accord investigator 's opinion Known grade 4 allergic reaction E.Coli Lasparaginase ( accord NCICTCAE , Version 3.0 ) History grade 3 transfusional incident Presence specific antierythrocyte antibody prevent get compatible erythrocyte concentrate patient Patient concomitant treatment likely cause hemolysis Patient undergo yellow fever vaccination Patient phenytoin treatment Patient include previous clinical study le 6 week ago</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>acute lymphoblastic leukemia</keyword>
	<keyword>relapse</keyword>
	<keyword>asparaginase</keyword>
</DOC>